ORLANDO, Florida (Reuters) - A study of blockbuster drug Avastin in colon cancer patients who have undergone surgery showed that the drug's effectiveness wore off after patients stopped taking it, ...
– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...
The UK's National Institute for Health and Clinical Excellence (NICE) announced in a draft guidance it will not approve Roche's breast cancer drug Avastin (bevacizumab) due to "too many ...
– In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28% – – Up to 80% of people with ...
November 18, 2011 — The US Food and Drug Administration (FDA) announced today that it is rescinding its approval of bevacizumab (Avastin, Genentech) for treating metastatic breast cancer because the ...
December 9, 2011 (San Antonio, Texas) — Mere weeks after the US Food and Drug Administration (FDA) rescinded approval of the use of bevacizumab (Avastin, Genentech) in metastatic breast cancer, a new ...
I covered the FDA's Oncologic Drugs Advisory Committee this week, which, not surprisingly, turned out to be the most emotional FDA hearing I've covered in my three years on this beat. Not surprising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results